CRIS, Curis (formerly CBMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI)

CRIS 1.260

-3.8%

Nov 11 3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (363)	3/2/2001 12:56:33 PM
From: Jim Oravetz	Read Replies (1) of 668

Among those are Curis (CRIS) now selling at $6/share after the FDA didn't approve OP1 being reviewed for a subset of bad bone fractures-Curis subsequently got approval in Australia and in the long run if their partner Stryker pursues it they will most probably get approval in the US. However this company has many other irons in the fire including a protein called Hedgehog, which is known to be involved in early fetal development and patterning. Curis has recently demonstrated that Hedgehog in combination with other biologic agents can keep stem cells growing in culture-and this kind of technology will be important in many areas of medicine in the future. They also have very interesting data on the relationship of Hedgehog to basal cell skin cancer, one of the most prevalent cancers and one that frequently requires disfiguring facial surgery. Other important products in the pipeline include a line of tissue replacement parts and implantable gels for urinary problems. I think the stock's dive caused by recent FDA action in conjunction with a down market creates a great entry point for Curis-but be prepared to hold for the long run. biospace.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next